JPMorgan downgraded G1 Therapeutics to Underweight from Neutral without a price target. The analyst’s cautious stance on the shares is based on potential near-term commercial headwinds for Cosela and the firm’s anticipation of Q3 quarterly miss. In addition, G1’s pipeline “has more to prove,” in particular with trilaciclib readouts in Q1 of 2024, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GTHX: